SIRAKOSS received approval under the CE Mark for Osteo3 nanosynthetic bone graft substitute, intended to fill skeletal voids or gaps on its own or in combination with autograft or allograft.
The company is developing further generations of Osteo3 that will require little or no preparation in the O.R.
SIRAKOSS received approval under the CE Mark for Osteo3 nanosynthetic bone graft substitute, intended to fill skeletal voids or gaps on its own or in combination with autograft or allograft.
The company is developing further generations of...
SIRAKOSS received approval under the CE Mark for Osteo3 nanosynthetic bone graft substitute, intended to fill skeletal voids or gaps on its own or in combination with autograft or allograft.
The company is developing further generations of Osteo3 that will require little or no preparation in the O.R.
Copy to clipboard 
